From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies.
Introduction
Over the past 50 years, there have been dramatic improvements in the outcome of children with acute lymphoblastic leukemia (ALL): 5-year overall survival is now approaching 90%. [1] [2] [3] During this period, the Pediatric Oncology Group (POG) focused on risk-adapted therapy attempting to both limit toxicities and to maximize cures. Early studies for patients with lower-risk B-precursor ALL focused on antimetabolite-based therapy, avoiding the use of anthracyclines, alkylating agents and epipodophyllotoxins. Because patients with higher risk B-precursor ALL had an inferior outcome with antimetabolitebased therapy alone, further studies investigated the Goldie-Coldman hypothesis by the alternating use of anti-tumor agents that are relatively non-cross resistant to prevent the emergence of (or to treat) drug-resistant leukemic clones.
Leukemic cells from children with T-cell ALL and Infant ALL have different biological characteristics compared with those of children with B-precursor ALL. Therefore, these patients were treated on lineage-and age-specific protocols. Children with T-cell ALL were initially treated with rotating chemotherapeutic agents, including anthracyclines, alkylators and epipodophyllotoxins along with intensification of asparaginase. However, because of a high rate of secondary malignancies, subsequent studies focused on intensification with asparaginase and methotrexate. Infants proved difficult to treat throughout this period with high rates of relapse, despite the use of antimetabolites, anthracyclines, alkylators and epipodophyllotoxins.
From 1984 to 2001 the POG conducted seven studies for the treatment of B-precursor ALL, two for T-cell ALL and three for Infant ALL. In this paper, we report the long-term outcomes of patients enrolled on these studies.
Materials and methods

Patients
Between 1984 and 2001, 7393 patients diagnosed with ALL were enrolled on 12 POG studies. Patients with B-precursor ALL (n ¼ 6524) were X12 months to p21.999 years of age. Patients with L3 morphology were treated on other studies. Patients with T-cell ALL (n ¼ 705) were also X12 months to p21.999 years of age. Infants with ALL (n ¼ 164; POG 8398/8493/9107) were o12 months of age. The POG 8398 and 8493 infant ALL protocols included infants with B-precursor (non-L3 morphology) and the occasional infant with T-cell ALL. Infants with T-cell ALL were not eligible for POG 9107. For all studies, patients could not have received previous therapy except for emergent treatment with steroids and/or radiation for severe respiratory distress. Blasts were Sudan black and/or myeloperoxidase negative and non-specific esterase negative. Immunophenotyping, chromosome analysis and DNA index determination were performed at POG reference laboratories for all patients. On ALinC 16, patients also had reference laboratory fluoresence in situ hybridization testing for trisomies 4 and 10 and subsets of patients had molecular screening for TEL-AML1 (ETV6-RUNX1) and/or for MLL rearrangements. Infants on the 8398, 8493 and 9107 protocols had subsequent MLL testing from cryopreserved bone marrow samples. All studies were approved by the institutional review board for each participating center. Informed consent was obtained before registration and treatment.
Treatments B-Precursor ALL. Treatments are summarized in Table 1, and included three eras, Acute Leukemia in Children (ALinC) [14] [15] [16] . Each POG study was numbered so that the first two numbers indicated the anticipated start year and the second two numbers indicated the study number within the category. POG 8602 (ALinC 14) included patients with both lower and higher risk disease. Subsequently, patients with lower or higher risk disease were treated on separate POG studies. Four POG studies focused on patients with lower-risk disease (POG 9005, 9201, 9405 and 9605) and two POG studies focused on patients with higher risk disease (POG 9006 and 9406).
ALinC 14 (1986-1991) : POG 8602 evaluated four different schedules of antimetabolite-based therapy. [4] [5] [6] Patients with lower-risk disease had: age 1 to o 3 or 6 to o 11 years and white blood cell (WBC) o10 Â 10 3 /ml, or age 3 to o6 years and a WBC o 100 Â 10 3 /ml. Patients with higher risk disease had: age 1 to o 3 or 6 to o 11 years and WBC X10 Â 10 3 /ml, age 3 to o 6 years and WBC X100 Â 10 3 /ml, or age X11 years. Patients with central nervous system disease (CNS3) at diagnosis (blasts on cytospin of the cerebrospinal fluid with WBC X5 cells per ml), or liver and/or spleen extending below the umbilicus, or with pre-B ALL (cytoplasmic immunoglobulin positive) or with Philadelphia chromosome [t (9;22) ] positive blasts were considered as higher risk disease, regardless of age and WBC. Patients with lower-risk disease were randomized to one of the four post-induction regimens: (A) intermediate dose methotrexate (IDMTX) 1 g/m 2 , every 3 weeks Â 6; (B) IDMTX every 3 weeks Â 6 and L-asparaginase (Asp; Merck, West Point, PA, USA) 25 000 IU/m 2 intramuscular (i.m.) weekly Â 24; (C) IDMTX and cytosine arabinoside (AC) 1 g/m 2 , every 3 weeks Â 6; or (D) IDMTX/AC every 12 weeks Â 6. Patients with higher risk disease by age and WBC or by liver/spleen measurement were randomized to regimens B, C or D. Patients with pre-B ALL were randomized to regimen B or C. Patients who had t(9;22) or CNS3 were non-randomly assigned to regimen C. All patients received CNS prophylaxis with triple intrathecal therapy (TIT) including methotrexate, cytosine arabinoside and hydrocortisone. Patients with CNS3 at diagnosis received craniospinal irradiation. AlinC 15 (1991 AlinC 15 ( -1994 : ALinC 15 evaluated three schedules of increased intensity methotrexate/mercaptopurine therapy for patients with lower-risk disease (POG 9005). 7 Patients with higher risk disease received increased intensity methotrexate/ mercaptopurine with or without the addition of epipodophyllotoxins, anthracyclines and cytosine arabinoside (POG 9006). 8 Patients were risk classified based on age and WBC in the same manner as the POG 8602. Patients with CNS3, t(9;22), t (1:19) or testicular disease were classified as higher risk disease, regardless of age and WBC. Patients with higher risk disease based on age and WBC, no CNS3 disease and a DNA index (flow cytometric measurement of the DNA of the leukemic blast compared with a normal cell) of 41.16 were risk adjusted into the lower-risk group and treated on the POG 9005. Patients enrolled on the POG 9005 were randomized into three regimens: (A) IDMTX (1g/m 2 ) and intravenous intermediate dose mercaptopurine (IDMP) 1 g/m 2 every 2 weeks Â 12; (B) oral MTX (30 mg/m 2 every 6 h Â 6) and IDMP every 2 weeks Â 12; or (C) IDMTX every 2 weeks Â 12. Patients enrolled on POG 9006 were randomized into two regimens: (A) IDMTX/IDMP every 2 weeks Â 12 or (B) rotating cycles of IDMTX/IDMP, teniposide (VM26)/AC and prednisone/vincristine/daunomycin/Asp/AC (PVDAsp/AC). Patients with t(9;22), t(1;19), or testicular disease were non-randomly assigned to regimen A. Patients with t(9;22) could proceed to transplant at investigator's choice. POG 9006 was later amended to pilot regimen C, which was identical to regimen B except that the IDMTX was 2.5 g/m 2 . All patients received CNS prophylaxis with TIT and patients with CNS3 at diagnosis received craniospinal irradiation.
ALinC 16 (1994-1999) : ALinC 16 risk stratified patients into lower risk (POG 9201), 9 standard risk (POG 9405 and 9605), [10] [11] [12] and higher risk disease (POG 9406). This series first stratified based on age and WBC by National Cancer Institute (NCI) risk grouping: (1) standard riskFage 1-9 years and WBC o 50 Â 10 3 /ml, or (2) high riskFage X10 years or WBC X50 Â 10 3 /ml. 13 Patients with NCI standard risk and either (1) uninformative cytogenetics and DNA index 41.16, or (2) trisomies 4 and 10 were classified as having lower-risk disease. Patients with NCI standard risk and (1) uninformative cytogenetics and DNA index p1.16 (or technically unsatisfactory DNA index), or (2) an abnormal karyotype but lacking trisomies 4 and 10; or NCI high risk and (1) uninformative cytogenetics and DNA index 41.16, or (2) trisomies 4 and 10 were placed in the standard risk group. Patients with NCI high risk and (1) uninformative cytogenetics and DNA index p1.16 (or technically unsatisfactory DNA index) or (2) an abnormal karyotype but lacking trisomies 4 and 10; or patients with CNS3, t(1;19), t(4;11), or t(9;22) regardless of NCI risk group were placed in the higher risk group. POG 9201, designed to confirm previous outcomes, was a single regimen study using IDMTX for patients with lower-risk disease. POG 9405 randomized standard risk patients to two doses of IDMTX (1 versus 2.5 g/m 2 ) during intensification and to daily versus twice daily MP during continuation. POG 9405 was closed early because of neurotoxicity and replaced by POG 9605; only results from POG 9605 are reported with the ALinC 16 data. POG 9605 randomized patients in a 2 Â 2 factorial design to i.m. MTX (regimens A/C) versus divided dose (dd) MTX (regimens B/ D) 14, 15 and daily (regimens A/B) versus twice daily (regimens C/ D) MP. POG 9406 evaluated rotating cycles of relatively noncross-resistant agents and randomized in a 2 Â 2 factorial design to IDMTX, 1 g/m 2 (regimens A/B) versus 2.5 g/m 2 (regimens C/D) and to VM26/AC (regimens A/C) versus high-dose AC (3 g/m 2 every 12 h Â 4) (HDAC, regimens B/D). All ALinC 16 patients initially received CNS prophylaxis with TIT. Sixteen percent of patients enrolled on 9406/9605 developed grade 3-4 neurotoxicity (60% consisting of seizures). Subsequently, all patients were switched to intrathecal (IT) MTX alone on 9201/9406/ 9605. Patients with CNS3 at diagnosis received craniospinal irradiation.
T-cell ALL. POG 8704 16 (1987-1992 ) randomized patients to þ /À Asp (Merck) 25 000 IU/m 2 i.m. weekly Â 20, beginning on day 99 of therapy. The backbone of therapy consisted of rotating combinations including antimetabolites, alkylating agents, anthracyclines and epipodophyllotoxins. All patients received TIT for CNS prophylaxis. Patients with initial WBC 450 Â 10 3 /ml received cranial irradiation and patients with CNS3 at diagnosis received craniospinal irradiation.
POG 9404 17 (1996-2001) randomized patients in a 2 Â 2 factorial design to þ /À high-dose MTX (5 g/m 2 ) Â 4 doses and to þ /À dexrazoxane before doxorubicin infusions [18] [19] [20] [21] 22, 23 All infants received CNS prophylaxis with TIT; infants with CNS3 received additional doses of IT therapy during induction. POG 8493 cycles included VP16/AC, VP/Cy/AC and MTX/MP. 22, 23 All infants received CNS prophylaxis with TIT; infants with CNS3 received four additional doses of IT therapy during induction. POG 9107 cycles included HDAC/D, VP16/AC, IVMTX/IVMP and VP/Cy/AC. All infants received CNS prophylaxis with TIT; no additional therapy was given to patients with CNS3 disease.
Statistical considerations
Event-free survival time was defined as the time from diagnosis to first event (induction failure, relapse, death or second malignant neoplasm) or last contact for those who did not have an event. Overall survival time was defined as time from diagnosis to death or last contact. Event-free survival (EFS) and overall survival (OS) rates were computed by the method of Kaplan-Meier and were compared using the log-rank test. 24 Cox proportional hazards regression was used to identify independent prognostic factors for EFS. For patients who achieved complete remission (CR), cumulative incidence rates of isolated CNS or any (isolated plus combined) CNS relapse, therapy- related second malignancies and remission deaths were computed and compared using Gray's method adjusting for competing events. 25 Data sets were frozen as of 21 January 2009 for the analyses.
Results
The 10-year EFS rate improved significantly across eras for patients with B-precursor ALL enrolled on ALinC14 (1986-1991), ALinC15 (1991-1994) and ALinC16 (1992-1999): 66. 7 ± 1.2%, 68.1 ± 1.4% and 73.2 ± 2.1%, respectively (Po 0.0001; Figure 1a ). The 10-year OS rates for the three eras were 78.8 ± 1.0%, 82.8 ± 1.1% and 85.3 ± 1.7%, respectively (Po 0.0001; Figure 1b ). Similar improvements were seen for patients with T-cell ALL on POG 8704 (1987) (1988) (1989) (1990) (1991) (1992) Table 2a gives EFS and OS for ALinc14. Table 2b summarizes the outcomes by randomized regimens on POG 8602. Patients with lower-risk disease receiving IDMTX (regimen A) had an EFS of 76.3 ± 3.1% and did not have better outcomes with the addition of Asp or AC. Patients with higher risk disease had an EFS of 58% with both of the IDMTX/AC regimens. Patients with pre-B ALL treated with IDMTX/AC at 3 week intervals (regimen C) had an improved outcome compared with those treated with IDMTX/Asp (regimen B) EFS of 70.3 ± 2.9% versus 63.2 ± 3.6%, respectively (P ¼ 0.0246). Table 2c gives a summary of response and first events overall and by NCI risk group. The NCI standard risk patients had a CR rate of 98.2%, whereas the higher risk patients had a CR rate of 93.4% on this series. Induction failure and induction death rates for the standard risk patients were 0.52 and 0.81%, respectively. Corresponding rates for the higher risk patients were 4.5 and 1.9%, respectively. Table 2d gives the cumulative incidence rates both overall and by study. The 10-year cumulative incidence rates for isolated CNS and any CNS relapses on ALinC 14 were 4.3 ± 0.5 and 7.7 ± 0.6%, respectively (Figure 1c ). Cumulative incidence of secondary malignancies at 10 years was 0.6 ± 0.2%, and the incidence rate for remission deaths was 1.9 ± 0.3%. (Figure 1d , Table 2d ). Cumulative incidence of secondary malignancies at 10 years was 0.8 ± 0.2%, and the incidence rate for remission deaths was 1.4±0.3%. Cumulative incidence rates for secondary malignancies at 10 years were 0.7 ± 0.2 and 1.2 ± 0.5% on POG 9005 and 9006, respectively. Remission death rates on the two studies were 0.8 ± 0.3 and 2.8 ± 0.7%, respectively. had an EFS of 73.4±1.8% (POG 9605). There was a significant interaction between the two randomizations on that study, resulting in insufficient power to determine the superior regimen. Patients with higher risk disease (POG 9406) had EFS of 63.5 ± 1.7% and did not have improved outcomes with the use of HDAC or higher dose MTX. Table 2c gives a summary of response and first events overall and by NCI risk for ALinC16. The NCI standard risk patients had a CR rate of 99.0%, whereas the higher risk patients had a CR rate of 97.2% on this series. Induction failure and induction death rates for the standard risk patients were 0.23 and 0.29%, respectively. Corresponding rates for the higher risk patients were 1.5 and 1.0%, respectively. Cumulative 10-year incidence rates on ALinC16 for isolated CNS and any CNS relapses were 3.2±0.3 and 6.1 ± 0.5%, respectively (Figure 1e , Table 2d ). Overall incidence of secondary malignancies and remission deaths were 0.8 ± 0.2 and 2.0 ± 0.4%, respectively. Incidence of secondary malignancies at 10 years was 0.3±0.2%, 0.7±0.3% and 1. (Table 3b) . Table 3c gives a summary of response and first events for this study. The CR rate at the end of induction was 95.3%. Induction failure and induction death rates were 1.5 and 2.6%, respectively. Overall cumulative incidence rates at 10 years for isolated CNS and any CNS relapses were 3.4±1.0 and 9.8±1.7%, respectively (Figure 2c , Table 3d ). Overall rate for secondary malignancies at 10 years was 4.0±1.1%. Secondary malignancy rates at 10 years were 6.3 ± 1.9 and 1.9 ± 1.1% for patients receiving or not receiving weekly asparaginase (P ¼ 0.11). There were a total of 14 secondary malignancies (10 acute myeloid leukemia (AML), 1 myelodysplastic syndrome, 1 acute lymphoid leukemia, 1 angiocentric lymphoma and 1 primitive neuroectodermal tumor). Overall 10-year remission death rate was 3. Table 3a ). Patients had an improved outcome with the addition of HDMTX with a 10year EFS of 78.0±6.0 versus 65.8±7.3% (P ¼ 0.029; Table 3b ). The addition of dexrazoxane had no impact on EFS. Table 3c gives a summary of response and first events for this study. The CR rate at the end of induction was 91.5%. Induction failure and induction death rates were 7.4 and 0.83%, respectively. The 10year cumulative incidence rates for isolated CNS and any CNS relapses were 7.0±1.4 and 9.4±1.6%, respectively (Figure 2d , Table 3d ). Secondary malignancies developed in 2.8 ± 1.2%, and remission deaths occurred in 1.9±0.8% of patients. There were a total of eight secondary malignancies (three AML, one myelodysplastic syndrome, two non-Hodgkin's lymphoma, one right cranial tumor and one medulloblastoma). The 10-year cumulative incidence of secondary malignancies were 1.3±0.9 and 4.2 ± 2.2% on the No Dexrazoxane vs Dexrazoxane regimens (P ¼ 0.15). Secondary malignancy rates on the No HDMTX vs HDMTX regimens were 4.1 ± 2.3 and 2.3 ± 1.3% (P ¼ 0.81), respectively.
Infant ALL. For the 164 evaluable infants on POG 8398
(1984-1990), POG 8493 (1984) (1985) (1986) (1987) (1988) (1989) (1990) and POG 9107 (1991) (1992) (1993) , the overall 10-year EFS and OS rates were 24.1 ± 4.0 and 33.7±4.4%, respectively (Figure 3a ). The CR rates (Table 4b) at the end of induction on the three studies were 93.9, 89.3 and T-cell ALL. Univariate analyses are summarized in Table 3a for T-cell ALL. All 705 patients were part of the multivariate Cox regression analyses, which included NCI risk, gender, age, race, WBC and CNS status as prognostic factors (Table 5 ). Gender was a significant predictor of EFS (HR: 1.744, P ¼ 0.0005); male patients had worse outcomes. No other factors were predictive in the multivariate model. Long-term results of COG ALL studies Infant ALL. Univariate analyses are summarized in Table 4a for Infant ALL. Multivariate analyses included lineage (B-precursor vs T), gender, race, WBC, CNS status and presence of t(4;11) translocation in the model (Table 5 ). A total of 148 patients had complete data and were included in the analysis. Patients with 50oWBCo100 Â 10 3 /ml (HR: 2.132, P ¼ 0.0093) and WBCX100 Â 10 3 /ml (HR: 2.45, P ¼ 0.0003) had worse outcomes compared with WBCo50 Â 10 3 /ml. Presence of the t(4;11) translocation tended to predict poorer outcomes (HR: 1.53, P ¼ 0.056).
Discussion
B-Precursor ALL ALinC 14. All patients received antimetabolite-based therapy, which was less effective for patients with higher risk disease. No regimen was superior in either risk group, although it should be noted that patients with higher risk disease were not randomized into regimen A (IDMTX alone). In subgroup analysis, patients with pre-B ALL had an improved outcome with every 3-week IDMTX/AC versus every 3-week IDMTX and ALinC 15. POG 9005 intensified therapy by compression of MTX intensification cycles to every 2 weeks (from every 3 weeks on the 8602). In addition IDMP was added to the courses of either IDMTX or PO MTX during intensification. IDMTX/IDMP was superior to PO MTX/IDMP. 7 However, these results showed no improvement over those obtained on the POG 8602 with IDMTX every 3 weeks without IDMP. In addition, results with IDMTX alone (regimen C) were similar to results of IDMTX/ IVMP (regimen A). These data indicated that IDMP did not add benefit to IDMTX. The incidence of acute neurotoxicity was increased on regimens A and C of this trial that included IDMTX every 2 weeks (8.3 and 11.2%, respectively) compared with PO MTX/IDMP, 3.7% (Po0.001). The addition of IDMP to IDMTX did not increase the incidence of acute neurotoxicity over IDMTX alone. 26 Neurotoxicity on the POG 9005 was higher than the 2.6% reported on the POG 8602 where IDMTX was administered every 3 weeks. 5 Further analyses of the neurotoxicity (mostly seizures) suggested that this was because of a combination of an increased frequency and cumulative dose of IDMTX, an increased methotrexate:leucovorin ratio and the timing of leucovorin in relation to the intrathecal treatments. There was no evidence implicating an increased risk of neurotoxicity with the use of TIT. Early results of POG 9006 suggested an improved outcome for higher risk patients treated with rotating cycles of agents, resulting in early trial closure. However, longer follow-up showed no differences in EFS, although toxicity was increased with the rotating cycles of agents. 8 This may indicate that agents chosen to test the Goldie-Coldman hypothesis were either not equally effective or were cross resistant. In addition, the more intensive every 2-week IDMTX/IDMP regimen, like on the POG 9005, provided no improvement in the outcome compared with higher risk patients treated on POG 8602.
ALinC 16
POG 9201, using regimen A of POG 8602 confirmed our earlier favorable results for very low risk patients treated with IDMTXbased therapy. 9,27-29. The POG 9405 was closed early because of excessive grade 2-4 neurotoxicity (common toxicity criteria 2.0) (19% of patients, n ¼ 57). More than half of these events were seizures. Other events included cerebellar and motor deficits, cognitive dysfunction, headaches and significant fatigue. Neither the efficacy nor toxicity of the two MTX schedules could be fully evaluated. 10 POG 9605 replaced this study and returned to the intensification regimen A of POG 8602. 14, 15 Excessive neurotoxicity was again seen, and the study was amended to replace TIT with IT MTX. Further analysis of neurotoxicity, however, suggested the cause was more complex (see discussion of ALinC 15 above). There was no evidence implicating an increased risk of neurotoxicity with the use of TIT. Although there were no significant differences in outcomes within the MTX and MP study questions, when reviewed by Table 3c T-Cell ALL: response and event summary by study This suggested that the manner in which these antimetabolites were given influenced outcomes. However, because this trial was designed as a 2 Â 2 factorial, it was not powered to compare the four arms. 11, 12 Higher risk patients, POG 9406, received rotating cycles of non-cross resistant agents based on the early results of POG 9006. Patients were randomized between two doses of IDMTX based on results suggesting that higher steady state MTX levels would improve outcomes and HDAC/Asp versus VM26/AC in an attempt to improve outcomes without increasing the risk of secondary malignancies associated with epipodophyllotoxins. Neither of these strategies improved outcomes. ALinC 14-16. The incidence of isolated CNS relapse in patients enrolled on ALinC 14-16 was 3.2-4.8%. at 10 yrs, with prophylactic age-adjusted IT therapy for all patients and irradiation for patients with CNS3 disease at diagnosis. Despite more aggressive therapy, the incidence of isolated CNS relapse was increased in higher versus lower-risk patients, 5.8 ± 0.5 versus 3.2±0.3%, respectively, emphasizing the more resistant nature of the leukemic clone in higher risk patients and suggesting that either the chemotherapeutic agents or their dosing regimens did not provide adequate CNS penetration. A decrease in isolated CNS relapse rate was seen on the POG 9406 with the use of high-dose antimetabolite therapy versus intermediate dose antimetabolite therapy used on the POG 9006. Other agents with increased CNS penetrance, such as dexamethasone, were not used in these studies, but may have an important role in higher risk disease. Secondary malignancies remained about 1% across all studies, despite the use of epipodophyllotoxins in higher risk patients. Despite increasing intensity across the ALinC 14-16, the percent of patients who failed initial therapy but achieved long-term survival remained constant at approximately 50%. This is similar to findings of the Children's Cancer Group, where survival after relapse was not different between earlier and later trials conducted between 1988 and 2002. 30 T-cell ALL POG 8704. The backbone of rotating agents for this protocol was chosen based on previous combinations that were shown to be effective against T-cell ALL and non-Hodgkin lymphoma. 18,31-33. The addition of asparaginase improved the outcome, consistent with outcomes seen on the Dana-Farber Cancer Institute (DFCI) series, where consolidation included both additional doxorubicin and asparaginase. 34, 35 Although the rate of secondary malignancies was increased in patients with T-cell ALL receiving asparaginase, this did not reach statistical significance. However, it should be noted that this was a subgroup analysis, and when all patients enrolled on the POG 8704, T-cell ALL and lymphoblastic lymphoma 16 were included in the analysis. The use of asparaginase was associated with a significantly increased rate of secondary malignancies. This is consistent with other studies where epipodophyllotoxins were combined with asparaginase. 36 Because epipodophyllotoxins are highly bound to plasma proteins, an asparaginase-induced decrease in protein synthesis may result in an increase in the unbound epipodophyllotoxin fraction in the plasma and an increased risk of secondary malignancies. 37 POG 9404. The backbone of POG 9404 was based on the Dana-Farber Cancer Institute (DFCI) 87-01, which lacked epipodophyllotoxins but contained anthracyclines that resulted in late cardiac toxicity. The HDMTX regimens had improved outcomes because of decreased induction failures and CNS relapse rates and resulted in early closure of the No HDMTX regimens. 17 The addition of dexrazoxane did not have an adverse impact on the 10-year EFS. However, late effects of dexrazoxane on cardiac function are still to be determined. Secondary malignancies occurred in 2.8 ± 1.2% of patients, and were not associated with the use of HDMTX or dexrazoxane.
POG 8704/9404. The incidence of isolated CNS relapse in patients enrolled on POG 8704 and on POG 9404 was 3.4 and 7.0%, respectively, at 10 years. All patients received prophylactic age-adjusted IT therapy and all CNS3 and higher risk patients on 8704, as well as all patients enrolled on POG 9404, received CNS irradiation. Despite the universal application of CNS irradiation on POG 9404, CNS relapse rates did not decrease on this study. This may be a reflection of the limited use of prophylactic IT therapy on the POG 9404 versus 8704, where patients received fewer doses of IT, 10 versus 17, respectively. Overall secondary malignancies in T-cell ALL (2.8-4%) remained higher than that for patients with B-precursor ALL. Only 25% of relapsed T-ALL patients achieved long-term survival, significantly lower than similar patients with B-precursor disease. 
Infant ALL
Throughout this period results were poor. Although there is a suggestion of improving outcomes, this did not reach statistical significance. The incidence of isolated CNS relapse in patients on POG 8398/8493/9107 was 3.4 ± 1.5% at 10 years, despite using no CNS irradiation certainly because of the poor neurocognitive outcome. There was one secondary malignancy at year 12 among the 148 patients in remission on these studies.
Prognostic indicators
Prognostic indicators identified on the POG studies are similar to those found by other investigators. Significantly, however, gender remained a prognostic indicator on both the B-precursor and T-cell ALL studies. On each of the POG studies, male and female patients were treated with the same duration of therapy. Gender has also been shown to be a prognostic indicator by others, who have chosen to treat males for a year longer than female patients. [38] [39] [40] [41] However, it is unclear whether longer duration or early intensification of therapy actually improves outcomes for male patients.
Conclusion
Over this series of studies we investigated the use of antimetabolite-based and rotating agent therapy for the treatment of ALL. The use of IDMTX (1 g/m 2 ) every 3 weeks improved outcomes for patients with B-precursor ALL. However, with the exception of HDMTX for the treatment of T-cell ALL, further intensification strategies were unsuccessful, suggesting that we have maximized our ability to eradicate drugresistant clones with antimetabolite-based therapy. In addition, the use of rotating agents had limited impact on higher risk disease. Although this may indicate that the Goldie-Coldman hypothesis is incorrect, it is also possible that the choice or schedule of the agents was not optimal, as other studies using rotating agents have improved outcomes. 39, 42, 43 The POG series has shown that patients with lower-risk B-precursor ALL can be successfully treated with antimetabolite-based therapy, and future studies will need to balance further improvements in the outcome against the toxicities associated with therapy. Patients with higher risk B-precursor ALL require therapy directed at early identification [44] [45] [46] [47] [48] and treatment of the resistant clone, and may include agents not explored on this series, such as dexamethasone or alkylators. A key strategy to improving the outcome of very high-risk patients will be to identify recurrent genetic lesions present in patient subgroups and develop molecularly targeted therapies directed at these lesions, as has been so effective in Ph þ ALL. Patients with T-cell ALL and infant ALL will require novel agents, 49, 50 as there is limited ability to further intensify therapy.
